




DOCKET NO.: 248336US0DIV

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

"RESPONSE UNDER 37 CFR 1.116-
EXPEDITED PROCEDURE EXAMINING
GROUP 1616"



ATTORNEYS AT LAW

STEPHEN G. BAXTER
(703) 413-3000
SBAXTER@OBLON.COM

RE: Application Serial No.: 10/766,857

Applicants: David LEWIS et al

Filing Date: January 30, 2004

For: PHARMACEUTICAL AEROSOL COMPOSITION
CONTAINING HFA 227 AND HFA 134A

Group Art Unit: 1616

Examiner: ALSTRUM ACEVEDO, J. H.

SIR:

Attached hereto for filing are the following papers:

AMENDMENT & REQUEST FOR RECONSIDERATION

Our credit card payment form in the amount of -0- is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. §1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. §1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Stephen G. Baxter

Registration No. 32,884

Customer Number

22850

(703) 413-3000 (phone)
(703) 413-2220 (fax)

Application No.: 10/766,857
Response to Official Action of October 12, 2006

"RESPONSE UNDER 37 CFR 1.116-
EXPEDITED PROCEDURE EXAMINING
GROUP 1616"

DOCKET NO: 248336US0DIV

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF

DAVID LEWIS, ET AL.

SERIAL NO: 10/766,857

FILED: JANUARY 30, 2004

FOR: PHARMACEUTICAL AEROSOL
COMPOSITION CONTAINING HFA 227
AND HFA 134A

:

: EXAMINER: J. ALSTRUM ACEVEDO

:

: GROUP ART UNIT: 1616

:

AMENDMENT & REQUEST FOR RECONSIDERATION

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

In response to the Office Action dated October 12, 2006, Applicants respectfully request reconsideration of the above-identified application in view of the following amendments and remarks.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 4 of this paper.